After the market closed on March 8, 2011, Finisar announced weak fiscal year 2011 third quarter results and fourth quarter projected revenues, which were lower than analysts’ estimates. As a result, Finisar’s stock fell nearly 39 percent, or $15.43 per share, to close at $24.61 per share on March 9, 2011.Hagens Berman’s investigation seeks to scrutinize the following allegedly concealed information: (a) The extent to which Finisar’s recent revenue surge was due to an inventory build by the Company’s customers; (b) Finisar’s experience of increasing pricing pressures due to intense competition in the industry, and as a result, being forced to concede to steep discounts in order to retain certain customers; and (c) Finisar’s experience of a serious slowdown in business from China. More information about the case is available at: www.hbsslaw.com/fnsr About Investor Fraud Practice Hagens Berman is a nationally recognized investor-rights law firm that provides highly acclaimed fraud recovery and asset protection services to individual and institutional investors who have been negatively affected by poor corporate governance, breach of fiduciary duties, misrepresentation of information, or a failure of good faith, fair dealing or loyalty. We have successfully prosecuted hundreds of cases including the recent class-action lawsuit against Charles Schwab & Co, which resulted in a $235 million settlement on behalf of investors. For an in-depth discussion of securities fraud, corporate governance and investor rights, please visit our Meaningful Disclosure blog. About Hagens Berman Seattle-based Hagens Berman Sobol Shapiro LLP is one of the top class-action law firms in the nation with offices in Boston, Chicago, Colorado Springs, Los Angeles, Phoenix, San Francisco and Washington, D.C. Founded in 1993, we represent plaintiffs in class actions and multi-state, large-scale litigation that seek to protect the rights of investors, consumers, workers and whistleblowers. More information about the firm is available at www.hbsslaw.com.
Hagens Berman Sobol Shapiro LLP reminds investors with losses exceeding $300,000 of the May 11 deadline to file for lead plaintiff status in the lawsuit against Finisar Corporation (the “Company” or “Finisar”) (NASDAQ:FNSR). The investor-rights law firm also advances its investigation into Finisar for securities fraud and insider selling allegations. A lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of purchasers of Finisar Corp. common stock during the proposed “Class Period” between December 2, 2010, and March 8, 2011. FNSR investors who purchased common stock from the Company during the Class Period and experienced losses exceeding $300,000 are encouraged to contact Hagens Berman partner Reed R. Kathrein at 510-725-3030 for a personal consultation. Investors may also contact the firm’s legal team at FNSR@hbsslaw.com. “We are closely investigating what senior management at Finisar knew when they sold stock in December 2010 and when they adopted stock sales plans in September and October,” said Mr. Kathrein, who is leading the investigation against Finisar. “Our concern is that they may have engaged in unusual insider selling at the end of 2010 when customers’ large inventory holdings and competitive pressures should have been recognized.” Hagens Berman is interested to speak with witnesses who may have additional information regarding these claims, as well as information about allegations that the company issued misleading and materially false financial statements. Based in Sunnyvale, Calif., Finisar is a seller of fiber optic subsystems and network components. The lawsuit alleges that Finisar and certain of its officers and directors violated sections of the Securities Exchange Act of 1934. Finisar may have artificially manipulated its stock price, which peaked at $43.23 per share on February 14, 2011, when the defendants concealed competitive pressures and decreased demand, the lawsuit states. Furthermore, the lawsuit states that Finisar failed to attribute its recent revenue growth to an oversupply of inventory in the market.